Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13300930 | 0.77 | CYP2D6 (0.47) | CYP2D6KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL20069040 | 0.75 | CYP2D6 (0.45) | CYP2D6KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL22856981 | 0.75 | CYP2D6 (0.45) | CYP2D6KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL13300914 | 0.75 | CYP2D6 (0.45) | CYP2D6KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL1764782 | 0.74 | — | — | |
| SCHEMBL12894699 | 0.74 | CYP2D6 (0.43) | CYP2D6KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL10111445 | 0.73 | CYP2D6 (0.46) | CYP2D6KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL8319997 | 0.72 | CYP2D6 (0.42) | CYP2D6KDM4EMEN1ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL1936868 | 0.72 | — | — | |
| SCHEMBL12563429 | 0.71 | GRIN2D (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787780-B2 | Quaternary indazole glucocorticoid receptor antagonists | CORCEPT THERAPEUTICS INCORPORATED (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230032612-A1 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787780-B2 | Quaternary indazole glucocorticoid receptor antagonists | NR3C1, NR3C2, MC2R | CYP2D6 303/4885KDM4E 3007/4885MEN1 4167/4885 |
| US-20230032612-A1 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, MC2R | CYP2D6 303/4885KDM4E 3007/4885MEN1 4167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.